中金引述2020年一份研究报告称，中国内地18岁以上人口高血脂症整体盛行率为35.6%，他汀类药物仍然是当地治疗高血脂症的主要药物，至于“PCSK9”抑制剂已于临床试验及商业化中证明其市场潜力。Kangfang Biotech's new drug marketing license application for ixining (inucimab, PCSK9) has been approved by the China Drug Administration.
The Zhitong Finance App learned that CICC released a research report stating that it maintains Kangfang Biotech's (09926) “outperforms the market” rating and that the profit forecast for the 2024 and 2025 fiscal years remains unchanged. In view of the progress of the company's various products and the improvement in the liquidity of H shares, the target price was raised by 28.6% to HK$90.
Kang Fang Biotech announced earlier that its new drug marketing license application for ixining (inucimab, PCSK9) has been approved by the China National Drug Administration. It is the company's first approved product in the non-oncology field, and the company's fifth independent innovative drug to enter the commercialization stage.
CICC quoted a 2020 research report as saying that the overall prevalence of hyperlipidemia among people aged 18 and over in mainland China is 35.6%. Statins are still the main local drugs for treating hyperlipidemia, and “PCSK9” inhibitors have proven their market potential in clinical trials and commercialization.
